Maverick Capital Ltd. Boosts Stake in uniQure N.V. $QURE

Maverick Capital Ltd. grew its position in shares of uniQure N.V. (NASDAQ:QURE) by 5.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 697,640 shares of the biotechnology company’s stock after acquiring an additional 35,820 shares during the period. Maverick Capital Ltd.’s holdings in uniQure were worth $11,406,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of QURE. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter valued at about $50,000. Torren Management LLC acquired a new stake in uniQure during the 4th quarter worth approximately $28,000. IFP Advisors Inc acquired a new stake in uniQure during the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC acquired a new stake in uniQure during the 4th quarter worth approximately $48,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 906 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Trading Down 2.0%

NASDAQ QURE opened at $38.21 on Tuesday. The company’s fifty day simple moving average is $36.20 and its 200-day simple moving average is $25.80. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market cap of $2.41 billion, a P/E ratio of -10.98 and a beta of 0.90.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Equities research analysts predict that uniQure N.V. will post -3.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Madhavan Balachandran sold 11,685 shares of uniQure stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director directly owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares in the company, valued at approximately $4,251,905.14. This trade represents a 20.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 433,229 shares of company stock worth $17,944,799 over the last quarter. Company insiders own 4.65% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Leerink Partners increased their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $25.00 to $65.00 in a research note on Thursday, June 18th. Royal Bank Of Canada lifted their target price on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, HC Wainwright upped their price target on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average target price of $64.17.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.